Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

New evidence that heart damage risk is much higher after COVID-19 infection than after vaccination

The new meta-analysis, published in Frontiers in Cardiovascular Medicine, included data from 58 million patients. “We hope our findings will help mitigate vaccine hesitancy and increase vaccine uptake," one researcher said. 

Thumbnail

CVS, Walgreens and Walmart ordered to pay $650M for role in opioid epidemic

Three major pharmacy names will have to fork over hundreds of millions of dollars to two Ohio counties for their roles in the opioid epidemic, a judge has ruled.

Thumbnail

Autoimmune patients caught in crossfire of Supreme Court's Roe decision

Some patients with certain autoimmune diseases are finding it difficult to obtain their prescriptions for methotrexate as a result of changing abortion care laws.

The American Medical Association (AMA) Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe. The policy was adopted at the AMA 2022 meeting. #AMA #AMA175 #AMAmtg #ASNC

AMA supports reimbursement for pharmacologic stress agent regadenoson

The American Medical Association Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe.

Novavax NVX-CoV2373 COVID-19 vaccine myocarditis

FDA committee backs Novavax's COVID-19 vaccine despite heart damage concerns

The committee's approval comes days after the FDA shared details on a small number of trial participants who developed myocarditis or pericarditis after receiving the vaccine.  

FDA asks drug makers to address shortages

Drug shortages have been impacted by COVID-19, with 95% of doctors believing the pandemic exposed weaknesses in the medicine supply chain.

The USPSTF changed the low-dose aspirin recommendations for cardiovascular disease prevention in April 2022 by suggesting patients over age 60 without history of CVD should not take it and people 40-60 should only take it if there are other risk factors.

VIDEO: USPSTF official discusses new low-dose aspirin recommendations

Michael J. Barry, MD, vice chair of the U.S. Preventive Services Task Force, gave Cardiovascular Business an overview of the new recommendations.

Thumbnail

USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup